Soft Tissue Sarcomas

Introduction & Etiology - The Sneaky Lumps

• Rare, malignant mesenchymal tumors originating from connective tissues (e.g., fat, muscle, nerve, blood vessels, deep skin tissues).
• Peak incidence: 40-60 years; slight male predilection.
• Etiology largely unknown for most; risk factors include:
  • Genetic syndromes: Neurofibromatosis type 1 (NF1), Li-Fraumeni (p53 mutation), Gardner syndrome.
  • Prior radiation therapy (latency period 5-15 years).
  • Chronic lymphedema (e.g., Stewart-Treves syndrome).
  • Chemical exposure (e.g., vinyl chloride, arsenic).
  • Trauma: role remains controversial.

⭐ Most soft tissue sarcomas arise de novo, not from pre-existing benign lesions.

Clinical Features & Diagnosis - Clues & Confirmation

• Clues: Most commonly a painless, progressively enlarging mass. Suspect malignancy if:
  • Size >5 cm (often compared to a golf ball)
  • Deep to fascia (not superficial)
  • Rapid growth or newly painful
  • Fixed to underlying structures
• Confirmation:
  • Imaging:
    • X-ray/USG: Initial; assess calcification, cystic vs solid nature.
    • MRI: Key for local staging (size, depth, neurovascular relation, involved compartments).
    • CT Chest: Screens for lung metastases (most common site).
  • Biopsy: Essential for definitive diagnosis & grading. Image-guided core needle biopsy is standard. Incisional if core non-diagnostic. Crucially, avoid unplanned excisions.

⭐ MRI is the imaging modality of choice for local staging of soft tissue sarcomas.

Staging & Grading - Sizing Up the Foe

• Staging (AJCC 8th Ed.):
  • T (Tumor): Size & depth. T1: ≤5cm; T2: >5-10cm; T3: >10-15cm; T4: >15cm. 'a' superficial, 'b' deep.
  • N (Nodes): N0 (no nodes), N1 (regional nodes).
  • M (Metastasis): M0 (no distant mets), M1 (distant mets).
• Grading (FNCLCC): Crucial for prognosis.
  • Score: Sum of Differentiation, Mitotic count, Necrosis.
  • Grades: G1 (Score 2-3), G2 (Score 4-5), G3 (Score 6-8).

⭐ Tumor grade (especially FNCLCC) is one of the most important prognostic factors in localized soft tissue sarcoma.

Common STS Types - Know Your Villains

• Liposarcoma: Most common adult STS. Well-differentiated (MDM2 amp), Myxoid (t(12;16) FUS-DDIT3), Pleomorphic.
• Leiomyosarcoma: Smooth muscle. Uterus, retroperitoneum. Spindle cells, cigar-shaped nuclei.
• Rhabdomyosarcoma: Commonest childhood STS. Skeletal muscle origin. Embryonal (botryoid), Alveolar (t(2;13) PAX3-FOXO1).
• Synovial Sarcoma: Young adults, near joints (knee). Biphasic/monophasic.

  ⭐ Synovial sarcoma is characterized by the t(X;18) (SYT-SSX) translocation.

• MPNST: Malignant Peripheral Nerve Sheath Tumor. From peripheral nerves/neurofibromas. Strong NF1 association. S100 variable.
• UPS: Undifferentiated Pleomorphic Sarcoma (formerly MFH). Exclusion diagnosis. Storiform pattern.
• Angiosarcoma: Endothelial. Skin, breast (post-radiation). CD31, CD34 positive.

Management Principles - Battling the Bulk

• Multidisciplinary Team (MDT) approach is crucial.
• Staging (TNM) guides treatment strategy.

⭐ The cornerstone of curative treatment for localized soft tissue sarcoma is wide surgical excision with negative margins.

• Surgery: Wide local excision (WLE) aiming for R0 (negative) margins. Limb salvage preferred.
• Radiotherapy (RT):
  • Neoadjuvant: ↓tumor size, ↑resectability.
  • Adjuvant: ↓local recurrence for high-grade/large tumors.
• Chemotherapy (CTx):
  • Adjuvant/Neoadjuvant: For high-risk, chemosensitive subtypes (e.g., Synovial Sarcoma). Doxorubicin-based.
  • Palliative: For metastatic disease.

High‑Yield Points - ⚡ Biggest Takeaways

• MRI is crucial for local staging of soft tissue sarcomas.
• Core needle biopsy is preferred for diagnosis; longitudinal incision for open biopsy.
• Wide local excision with negative margins is the treatment cornerstone.
• Adjuvant radiotherapy for large, high-grade tumors improves local control.
• Lungs are the most common site of distant metastasis.
• Adults: Undifferentiated Pleomorphic Sarcoma (UPS), Liposarcoma; Children: Rhabdomyosarcoma.
• Tumor grade is a critical prognostic factor.